

Research article

Open Access

Docosahexaenoic and eicosapentaenoic acids increase prion formation in neuronal cells

Clive Bate*¹, Mourad Tayebi¹, Luisa Diomedea², Mario Salmona² and Alun Williams¹

Address: ¹Department of Pathology and Infectious Diseases, Royal Veterinary College, Hawkshead Lane, North Mymms, Herts, UK. AL9 7TA and ²Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche 'Mario Negri', Via La Masa, 20156, Milan, Italy

Email: Clive Bate* - cbate@rvc.ac.uk; Mourad Tayebi - mtayebi@rvc.ac.uk; Luisa Diomedea - ldiomedea@marionegri.it; Mario Salmona - salmona@marionegri.it; Alun Williams - alunwilliams@rvc.ac.uk

* Corresponding author

Published: 12 September 2008

Received: 3 April 2008

BMC Biology 2008, **6**:39 doi:10.1186/1741-7007-6-39

Accepted: 12 September 2008

This article is available from: <http://www.biomedcentral.com/1741-7007/6/39>

© 2008 Bate et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: The transmissible spongiform encephalopathies, otherwise known as prion diseases, occur following the conversion of the cellular prion protein (PrP^C) to an alternatively folded, disease-associated isoform (PrP^{Sc}). Recent studies suggest that this conversion occurs via a cholesterol-sensitive process, as cholesterol synthesis inhibitors reduced the formation of PrP^{Sc} and delayed the clinical phase of scrapie infection. Since polyunsaturated fatty acids also reduced cellular cholesterol levels we tested their effects on PrP^{Sc} formation in three prion-infected neuronal cell lines (ScGT1, ScN2a and SMB cells).

Results: We report that treatment with docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) or the cholesterol synthesis inhibitor simvastatin reduced the amounts of free cholesterol in membrane extracts from prion-infected neuronal cells. Simvastatin reduced cholesterol production while DHA and EPA promoted the conversion of free cholesterol to cholesterol esters. Crucially, while simvastatin reduced PrP^{Sc} formation, both DHA and EPA significantly increased the amounts of PrP^{Sc} in these cells. Unlike simvastatin, the effects of DHA and EPA on PrP^{Sc} content were not reversed by stimulation of cholesterol synthesis with mevalonate. Treatment of ScGT1 cells with DHA and EPA also increased activation of cytoplasmic phospholipase A₂ and prostaglandin E₂ production. Finally, treatment of neuronal cells with DHA and EPA increased the amounts of PrP^C expressed at the cell surface and significantly increased the half-life of biotinylated PrP^C.

Conclusion: We report that although treatment with DHA or EPA significantly reduced the free cholesterol content of prion-infected cells they significantly increased PrP^{Sc} formation in three neuronal cell lines. DHA or EPA treatment of infected cells increased activation of phospholipase A₂, a key enzyme in PrP^{Sc} formation, and altered the trafficking of PrP^C. PrP^C expression at the cell surface, a putative site for the PrP^{Sc} formation, was significantly increased, and the rate at which PrP^C was degraded was reduced. Cholesterol depletion is seen as a potential therapeutic strategy for prion diseases. However, these results indicate that a greater understanding of the precise relationship between membrane cholesterol distribution, PrP^C trafficking, cell activation and PrP^{Sc} formation is required before cholesterol manipulation can be considered as a prion therapeutic.

Background

Transmissible spongiform encephalopathies (TSEs), also known as prion diseases, include Creutzfeldt-Jakob disease and kuru in humans, scrapie in sheep and goats, and bovine spongiform encephalopathy in cattle. The central event in these diseases is thought to be the conversion of a host-encoded cellular prion protein (PrP^C) into an abnormally folded disease-associated isoform, designated PrP^{Sc} [1]. Aggregates of PrP^{Sc} accumulate around neurons in affected brain areas [2], a process which is thought to lead to neuronal dysfunction and the clinical symptoms of infection. PrP^{Sc} constitutes the major and perhaps the only component of the infectious particle [3].

The process of prion replication has been studied extensively in prion-infected neuronal cell lines. Treatment with some cholesterol synthesis inhibitors reduced the production of PrP^{Sc} in scrapie-infected neuronal cells [4-6]. The anti-prion effect of such drugs is attributed to cholesterol depletion affecting the formation of specialised membrane micro-domains called lipid rafts [7]. These lipid rafts are highly enriched in cholesterol, sphingolipids and gangliosides, and contain specific proteins [8]. The presence of a glycosylphosphatidylinositol (GPI) anchor that mediates the attachment of proteins including PrP^C and PrP^{Sc} to membranes, targets these proteins to lipid rafts [9].

Since cholesterol levels are a factor determining PrP^{Sc} formation [4-6], the effects of compounds reported to affect cellular cholesterol levels were examined. Polyunsaturated fatty acids (PUFA) are fatty acids which contain two or more double bonds within their hydrocarbon chain. They are taken as dietary supplements by large numbers of people for their perceived health benefits against a variety of diseases including coronary heart disease, hypertension, diabetes mellitus and rheumatoid arthritis [10]. The common PUFA include docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), arachidonic acid (AA), linoleic acid (LA) and linolenic acid (LNA) and in most cells PUFA are rapidly incorporated into phospholipids [11]. The incorporation of PUFA into phospholipids alters the composition and physical properties of cell membranes [12]. Since dietary PUFA reduce cellular cholesterol levels [13] the effects of PUFA on the composition of neuronal cell membranes and on the production of PrP^{Sc} were examined. We report that treatment with DHA or EPA significantly reduced the amounts of free cholesterol in ScGT1, ScN2a and SMB cells. However, in contrast to the effects of cholesterol synthesis inhibitors, treatment with DHA or EPA actually increased PrP^{Sc} formation. DHA or EPA treatment also increased the activity of phospholipase A₂ (PLA₂), an enzyme reported to affect PrP^{Sc} formation [14]. They also increased the amount of PrP^C, that is essential for the development of prion diseases [15,16], at

the cell surface, a putative site for PrP^{Sc} formation. In conclusion our data indicate that cholesterol depletion *per se* does not reduce PrP^{Sc} formation.

Results

DHA and EPA increase PrP^{Sc} in prion-infected neuronal cells

The effect of PUFA on the formation of PrP^{Sc} in ScGT1 cells was determined by daily treatment with 1 μ M PUFA for 7 days. Significantly higher amounts of PrP^{Sc} were found in cells treated with DHA (14.2 ng/ml \pm 1.7 compared with 8 \pm 1, n = 15, P = 0.00000000001) or EPA (13.8 ng/ml \pm 2.4 compared with 8 \pm 1, n = 15, P = 0.00000002) than in untreated cells, or cells treated with AA, LA or LNA (Figure 1A). Treatment with DHA or EPA did not affect the survival of ScGT1 cells (data not shown). Immunoblots were used to verify the ELISA data; these showed that there were observable differences in the amounts of PrP^{Sc} between untreated cells and cells treated with 1 μ M DHA or 1 μ M EPA (Figure 1B). In contrast, the amounts of β -actin in untreated cells and cells treated with DHA or EPA were not significantly different. Determina-




Figure 1
Treatment with DHA or EPA increases the PrP^{Sc} content of ScGT1 cells. (A) The amounts of PrP^{Sc} in ScGT1 cells treated for 7 days with 1 μ M PUFA as shown (n) or with control medium (h). Values shown are the mean average amounts of PrP^{Sc} (ng/ml) \pm SD, n = 15. # = PrP^{Sc} content significantly higher than that of control cells. (B) Immunoblots showing the amounts of β -actin and PrP^{Sc} in extracts from ScGT1 cells treated with control medium or 1 μ M DHA or EPA as shown.

tion of the effects of different PUFA on PrP^{Sc} formation in ScGT1 cells revealed that whereas treatment with either DHA or docosapentaenoic (DPA) significantly increased amounts of PrP^{Sc} present, treatment with docosatetraenoic acid (DTA) or LA did not. Similarly, while treatment with EPA increased the amounts of PrP^{Sc} in ScGT1 cells, treatment with eicosatetraenoic acid (ETA) did not. The effects of DHA, DPA and EPA on the PrP^{Sc} content of ScGT1 cells were dose-dependent (Figure 2).

To confirm that the effects of DHA or EPA were not specific for ScGT1 cells the amounts of PrP^{Sc} in ScN2a and SMB cells were also examined. The amounts of PrP^{Sc} in ScN2a cells treated for 7 days with 1 μ M DHA or 1 μ M EPA, but not in cells treated with LNA, LA or AA, were significantly higher than in untreated cells (Table 1). Similar results were obtained with SMB cells; treatment with DHA or EPA increased the amounts of cell-associated PrP^{Sc}. Since PrP^{Sc} can be released from cells as exosomes or as result of cell damage [17], the amounts of PrP^{Sc} in the supernatants of treated cells were also measured. The amounts of PrP^{Sc} in the supernatants of ScGT1, ScN2a or SMB cells treated with 1 μ M DHA or 1 μ M EPA were significantly higher than in supernatants from untreated cells (Table 1).




Figure 2
Dose-dependent effects of PUFA on PrP^{Sc} formation.
 The amounts of PrP^{Sc} in ScGT1 cells treated for 7 days with different concentrations of DHA (l), EPA (m), DPA (n), LA (n), DTA (h) or ETA (\diamond). Values shown are the mean average amounts of PrP^{Sc} (ng/ml) \pm SD, $n = 9$.

DHA and EPA reduced free cholesterol in ScGT1 cells

The effect of 24-hour exposure to PUFA on the cholesterol content of ScGT1 cell extracts was examined. Exposure to 1 μ M DHA or EPA, but not to LNA or LA, significantly reduced their free cholesterol content (Table 2). None of the PUFA tested had a significant effect on the amounts of protein in these extracts (data not shown). The amounts of free cholesterol in cells treated with DHA or EPA were similar to those in cells treated with 5 μ M simvastatin, which inhibits 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, the rate-limiting step in cholesterol synthesis [18]. However, total cholesterol is a combination of free cholesterol found in cell membranes and cholesterol esters. Simvastatin reduced the amounts of free cholesterol in cell extracts without affecting the amounts of cholesterol esters, resulting in a reduction in total cellular cholesterol. In contrast, the total cholesterol content of ScGT1 cells treated with DHA or EPA was not significantly altered, as the reduction in free cholesterol was accompanied by significant increases in the amounts of cholesterol esters. The addition of DHA or EPA to ScN2a or SMB cells had similar effects; they significantly reduced free cholesterol levels and increased the cholesterol ester content of these cells (data not shown).

Such observations raised the possibility that the increased amounts of cholesterol esters in prion-infected cells facilitate PrP^{Sc} formation. This possibility was examined by treating ScGT1 cells with 10 μ M cholesterol esters (cholesterol myristate or cholesterol arachidonate). We report that although treatment increased the amounts of cholesterol esters in ScGT1 cells, there were no significant differences in the amounts of free cholesterol in these cells (Table 2), indicating that the cholesterol esters were not hydrolysed. The addition of cholesterol esters did not affect PrP^{Sc} formation; there were no significant differences between the PrP^{Sc} content of vehicle-treated ScGT1 cells and ScGT1 cells treated for 7 days with 10 μ M cholesterol myristate (8.1 ng/ml \pm 1.2 compared with 7.9 \pm 1.0, $n = 8$, $P = 0.8$) or cholesterol arachidonate (8.1 ng/ml \pm 1.2 compared with 8.5 \pm 1.7, $n = 8$, $P = 0.6$). Similarly, the addition of cholesterol myristate or cholesterol arachidonate did not significantly affect the amounts of PrP^{Sc} in ScN2a cells or in SMB cells (data not shown).

Effects of DHA and EPA are not reversed by mevalonate

The effects of DHA and EPA on cellular cholesterol levels and PrP^{Sc} formation were compared with those of simvastatin. As shown in Figure 3A, the exposure of ScGT1 cells to 1 μ M DHA or EPA for 7 days significantly decreased the free cholesterol content of cell extracts, as did 5 μ M simvastatin. However, while the addition of 100 μ M mevalonate significantly increased the amounts of free cholesterol in simvastatin-treated cells (521 free cholesterol (ng/ml) \pm 45 compared with 356 ng/ml \pm 49, $n = 9$,

Table 1: Effects of PUFA on cell-associated and secreted PrP^{Sc}

Treatment	PrP ^{Sc} (ng/ml)					
	ScGT1 cells		ScN2A cells		SMB cells	
	Cell extracts	Supernatant	Cell extracts	Supernatant	Cell extracts	Supernatant
None	8.0 ± 1.0	1.42 ± 0.12	1.38 ± 0.14	0.45 ± 0.09	6.2 ± 1.1	3.1 ± 0.8
1 μM DHA	14.2 ± 1.7 *	4.64 ± 0.73 *	2.91 ± 0.71 *	1.12 ± 0.12 *	16.4 ± 3.7 *	5.7 ± 3.1 *
1 μM EPA	13.8 ± 2.4 *	3.42 ± 0.6 *	3.58 ± 0.52 *	0.96 ± 0.25 *	14.1 ± 2.2 *	4.8 ± 1.2 *
1 μM LA	8.4 ± 1.6	1.38 ± 0.21	1.43 ± 0.2	0.68 ± 0.4	7.7 ± 2.5	2.6 ± 0.75
1 μM LNA	7.8 ± 1.1	1.54 ± 0.46	1.63 ± 0.31	0.51 ± 0.22	7.1 ± 1.8	2.1 ± 1.15
1 μM AA	8.1 ± 1.5	1.56 ± 0.3	1.44 ± 0.3	0.59 ± 0.11	6.4 ± 1.5	2.5 ± 1.26

The amounts of PrP^{Sc} in cell extracts (10⁶ cells/ml) and in culture supernatants (equivalent to 10⁶ cells/ml) from prion-infected neuronal cells treated for 7 days with 1 μM PUFA as shown. Amounts of PrP^{Sc} were measured by PrP-specific ELISA and are expressed as the mean average PrP^{Sc} (ng/ml) ± SD of ScGT1 (*n* = 15), ScN2a (*n* = 10) and SMB cells (*n* = 9). * = amounts of PrP^{Sc} significantly different from that of untreated cells (*P* < 0.01).

P = 0.0002), it did not affect the amounts of free cholesterol in cells treated with DHA (423 ng/ml ± 40 compared with 415 ± 43, *n* = 9, *P* = 0.4) or EPA (451 ng/ml ± 37 compared with 428 ± 38, *n* = 9, *P* = 0.17). Rather, the addition of mevalonate to DHA-treated cells significantly increased the amounts of cholesterol esters (225 ng/ml ± 28 compared with 133 ± 31, *n* = 9, *P* < 0.01). Next we examined the effects of mevalonate on PrP^{Sc} formation in ScGT1 cells treated with simvastatin, DHA or EPA. The addition of 100 μM mevalonate significantly increased the amounts of PrP^{Sc} in simvastatin-treated cells (7.4 ng/ml ± 0.5 compared with 1.4 ± 0.9, *n* = 9, *P* = 0.00002). In contrast, it did not affect the amounts of PrP^{Sc} in ScGT1 cells treated with DHA (13.8 ng/mg ± 1.5 compared with 14.3 ± 0.9, *n* = 9, *P* = 0.4) or EPA (14.3 ng/mg ± 1.1 compared with 13.9 ± 1.5, *n* = 9, *P* = 0.8), indicating that the effect of DHA and EPA on PrP^{Sc} formation was not due to HMG-CoA reductase inhibition (Figure 3B).

DHA increases PLA₂ activity of prion-infected neuronal cells

Since the amounts of activated cytoplasmic PLA₂ (cPLA₂) in ScGT1 cells correlates with the amounts of PrP^{Sc} [19]

and PLA₂ inhibitors reduce PrP^{Sc} formation [14], the effects of PUFA on the activity of PLA₂ in ScGT1 cells was determined. We report that treatment with 1 μM DHA for 24 hours significantly increased the amounts of phosphorylated (activated) cPLA₂ in ScGT1 cells (152 units activated cPLA₂ ± 15 compared with 100 ± 9, *n* = 9, *P* = 0.00001). Treatment with 1 μM EPA for 24 hours also significantly increased amounts of activated cPLA₂ (142 units ± 13 compared with 100 ± 9, *n* = 9, *P* = 0.00001), but treatment with 1 μM AA, LA or LNA had no significant affect (Figure 4A). The addition of 10 μM cholesterol myristate did not affect activation of cPLA₂ in ScGT1 cells (100 units ± 11 compared with 98 ± 8, *n* = 9, *P* = 0.93). This effect of treatment with 1 μM DHA or EPA was specific for prion-infected cells and did not affect the amounts of activated cPLA₂ in GT1 cells or primary cortical neurons. To examine this relationship further we compared the amounts of PrP^{Sc} and activated cPLA₂ in ScGT1 cells treated with varying concentrations of DHA or EPA. There was a positive correlation between the amounts of activated cPLA₂ at 24 hours and the PrP^{Sc} content of cells after 7 days (Pearson coefficient = 0.847, *P* < 0.001) (Figure 4B).

Table 2: Effects of PUFA on the distribution of cholesterol in ScGT1 cells

Treatment	Cholesterol ng/ml		
	Total	Free	Esterified
None	590 ± 54	515 ± 29	75 ± 26
DHA (1 μM)	544 ± 39	411 ± 26 #	133 ± 31 @
EPA (1 μM)	553 ± 28	438 ± 25 #	115 ± 20 @
LNA (1 μM)	607 ± 26	548 ± 43	59 ± 18
LA (1 μM)	572 ± 74	495 ± 52	77 ± 28
Simvastatin (5 μM)	438 ± 46 *	354 ± 41 #	84 ± 32
Cholesterol myristate (10 μM)	762 ± 55 *	538 ± 51	224 ± 41 @
Cholesterol arachidonate (10 μM)	734 ± 47 *	545 ± 38	189 ± 32 @

The amounts of total, free and esterified cholesterol in extracts from ScGT1 cells treated for 24 hours with PUFA, simvastatin, or with cholesterol esters as shown. Amounts of total, free and esterified cholesterol were expressed as the mean average (ng/ml) ± SD, *n* = 9. Amounts of total cholesterol (*), free cholesterol (#) or esterified cholesterol (@) significantly different from that of untreated cells (*P* < 0.01).




Figure 3
The effects of DHA or EPA are not reversed by mevalonate. (A) The amounts of free cholesterol in extracts from ScGT1 cells treated for 7 days with control medium, 5 μ M simvastatin (Sim), 1 μ M DHA or 1 μ M EPA as shown (h), and with the addition of 100 μ M mevalonate (n). Values shown are the mean average amounts of free cholesterol (ng/ml) \pm SD, $n = 9$. # = amounts of free cholesterol significantly higher following the addition of mevalonate. (B) The amounts of PrP^{Sc} in ScGT1 cells treated for 7 days with control medium, 5 μ M simvastatin (Sim), 1 μ M DHA, 1 μ M EPA as shown (h) and with the addition of 100 μ M mevalonate (n). Values shown are the mean average amounts of PrP^{Sc} (ng/ml) \pm SD, $n = 9$. # = amounts of PrP^{Sc} significantly higher following the addition of mevalonate.

The cPLA₂ isoform is largely responsible for the release of AA and increased production of prostaglandins. Here we show that the amounts of prostaglandin E₂ (PGE₂) produced by ScGT1 cells was significantly increased by 24-hour treatment with 1 μ M DHA (577 \pm 89 pg/ml compared with 407 \pm 51, $n = 9$, $P = 0.0002$) or EPA (568 \pm 98 pg/ml compared with 407 \pm 51, $n = 9$, $P = 0.001$), but not by LA or LNA (Figure 5A). The addition of 1 μ M DHA or EPA did not affect PGE₂ production in GT1 cells. Furthermore, the increased amounts of PrP^{Sc} in DHA or EPA-treated ScGT1 cells showed a positive correlation with the amounts of PGE₂ produced (Pearson's coefficient = 0.749, $P < 0.001$; Figure 5B). Treatment with 1 μ M DHA also




Figure 4
DHA and EPA increases the amounts of activated cPLA₂ in ScGT1 cells. (A) The amounts of activated (phosphorylated) cPLA₂ in untreated ScGT1 cells (h) or ScGT1 cells treated with 1 μ M PUFA as shown (n). Values shown are the mean average amounts of activated cPLA₂ (units) \pm SD, $n = 12$. # = amounts of activated cPLA₂ significantly higher than that of untreated cells. (B) The amounts of activated cPLA₂ (units) in ScGT1 cells treated for 24 hours with different concentrations of DHA or EPA were plotted against the amounts of PrP^{Sc} (ng/ml) in ScGT1 cells treated for 7 days with the same concentrations of DHA (l) or EPA (m).

increased the production of PGE₂ in ScN2a cells (319 pg/ml \pm 29 compared with 220 pg/ml \pm 24, $n = 6$, $P < 0.01$) and in SMB cells (487 pg/ml \pm 89 compared with 355 pg/ml \pm 44, $n = 6$, $P < 0.01$).

DHA increases the surface expression of PrP^C

Since PrP^C is necessary for PrP^{Sc} formation [15,16], the effects of PUFA treatment on the expression of PrP^C were examined. These studies were initially performed on primary cortical neurons that do not contain the infectious PrP^{Sc} to avoid any possible confusion between PrP^C and PrP^{Sc}. Treatment with 1 μ M PUFA for 24 hours did not affect the total amounts of PrP^C in whole cell membrane extracts. Although PrP^C is normally found within lipid raft




Figure 5
DHA and EPA increase the amounts of PGE₂ in ScGT1 cells. (A) The amounts of PGE₂ produced by untreated ScGT1 cells (h) or by ScGT1 cells treated for 24 hours with 1 μ M PUFA as shown (n). Values shown are the mean average amounts of PGE₂ (pg/ml) \pm SD, $n = 9$. # = PGE₂ content significantly higher than that of control cells. (B) The amounts PGE₂ (pg/ml) in ScGT1 cells treated for 24 hours with different concentrations of DHA or EPA were plotted against the amounts of PrP^{Sc} (ng/ml) in ScGT1 cells treated for 7 days with the same concentrations of DHA (l) or EPA (m).

micro-domains [9], treatment with 2 μ M simvastatin caused the redistribution of PrP^C into the normal bulk membrane. In contrast, treatment with PUFA did not alter the distribution of PrP^C between lipid rafts and the bulk membrane (Table 3).

The amounts of PrP^C at the cell surface were measured by digesting neurons with phosphatidylinositol-specific phospholipase C (PI-PLC). PI-PLC digestion releases GPI-anchored molecules including PrP^C from the cell surface [20]. The amounts of PrP^C released by PI-PLC from 10⁶ cortical neurons treated with 1 μ M DHA or 1 μ M EPA for 24 hours were significantly higher than the amounts released from untreated neurons or neurons treated with 10 μ M cholesterol esters (Table 4). Treatment with DHA

or EPA for 24 hours also significantly increased the amounts of surface PrP^C in GT1 and ScGT1 cells. It is noteworthy that the amounts of PrP^C released by PI-PLC from untreated ScGT1 cells were significantly higher than from untreated GT1 cells (4.1 ng/ml \pm 0.8 compared with 1.8 \pm 0.6, $n = 12$, $P < 0.01$). The effect of DHA or EPA on cell surface PrP^C expression contrasted to that of simvastatin, which reduced surface PrP^C expression [21]. When the amounts of PrP^C at the surface of ScGT1 cells treated with different concentrations of DHA or EPA were plotted against the amounts of PrP^{Sc} in ScGT1 treated for 7 days with the same concentrations of DHA or EPA, a significant correlation was observed (Pearson coefficient = 0.832, $P < 0.001$) (Figure 6).

In a further set of experiments, treated cortical neurons were pulsed with membrane-impermeable biotin and the amounts of biotinylated-PrP^C in cell membranes were determined at time points thereafter. The amounts of biotinylated-PrP^C in neuronal extracts were reduced in a time-dependent manner. Significantly, in neurons treated with 1 μ M DHA or EPA the amounts of biotinylated PrP^C remaining in extracts after 3, 6, 12, 24 or 48 hours were significantly greater than those in extracts from untreated cells. While the half-life of biotinylated PrP^C in untreated neurons was approximately 4 hours, in DHA or EPA-treated neurons the half-life was increased to approximately 24 hours (Figure 7).

Discussion

The main goal of this study was to investigate the effects of PUFA on the production of PrP^{Sc}, a biochemical marker for the infectious agent of prion diseases. We report that treatment with DHA or EPA, but not with AA, LA or LNA, consistently increased the amounts of PrP^{Sc} within three prion-infected neuronal cell lines (ScGT1, ScN2a and SMB cells). This effect of PUFA correlated with the number of unsaturated bonds in the acyl chain; increased PrP^{Sc} content was observed in ScGT1 cells treated with DHA (six unsaturated bonds) and EPA or DPA (five), while treatment with PUFA containing four or less unsaturated bonds (AA, DTA, ETA, LNA or LA) did not affect PrP^{Sc} formation. The increased PrP^{Sc} content of DHA or EPA-treated cells was accompanied by increased PrP^{Sc} content of culture supernatants, indicating that this treatment did not prevent the release of PrP^{Sc} via exosomes or cell damage.

Cholesterol synthesis inhibitors disrupt lipid rafts and reduced PrP^{Sc} formation [4,5]. More recently, observations that cholesterol synthesis inhibitors delay experimental scrapie [22,23] increased the interest in the concept of cholesterol reduction as a means of treating prion diseases. PUFA are reported to reduce cellular cholesterol and here we show that treatment with DHA and

Table 3: Treatment with PUFA does not affect the amounts of PrPC in neuronal membranes

Treatment	PrPC (ng/ml)		
	Whole cell extract	Lipid raft fraction	Bulk fraction
None	31.6 ± 4.8	25.5 ± 2	2.9 ± 0.9
1 μM AA	30.2 ± 3.1	26.8 ± 2.9	2.8 ± 0.5
1 μM DHA	33.2 ± 4.4	26.6 ± 3.4	3.8 ± 0.8
1 μM EPA	34.5 ± 2.9	27.8 ± 3.1	3.1 ± 0.3
1 μM LA	29.9 ± 4.1	25.9 ± 2.8	3.4 ± 0.8
1 μM LNA	28.8 ± 4.7	24.5 ± 2	3.5 ± 1.2
2 μM Simvastatin	35.6 ± 4.2	7.2 ± 2.2 *	25.9 ± 3.8 *

The amounts of PrPC in whole cell extracts, detergent insoluble membranes (lipid raft fraction) and the detergent soluble membrane (bulk fraction) from primary cortical neurons treated with 1 μM PUFA or 2 μM simvastatin for 24 hours. Amounts of PrPC were measured by ELISA and are expressed as the mean average PrPC (ng/ml) ± SD, n = 12. * = amounts of PrPC significantly different from that of untreated cells (P < 0.01).

EPA significantly reduced the free cholesterol content of ScGT1 cells. However, the effects of DHA or EPA on cellular cholesterol differed from those of the HMG-CoA inhibitor simvastatin. For example, treatment with simvastatin, but not with DHA or EPA, significantly reduced total cholesterol levels. The reduction in free cholesterol levels seen in ScGT1 cells treated with DHA and EPA was accompanied by a significant increase in the amounts of

cholesterol esters, and the total cholesterol content of DHA and EPA-treated cells was not significantly different from that of untreated cells. Although the increase in the PrP^{Sc} content of DHA and EPA-treated cells was accompanied by an increase in cholesterol esters, the addition of cholesterol esters did not increase PrP^{Sc} formation, suggesting that the relationship between cholesterol esters and PrP^{Sc} is casual rather than causal. Furthermore, the effects of DHA and EPA on cholesterol ester formation were independent of prion-infection; DHA and EPA increased cholesterol esters in uninfected N2a or GT1 cell lines and in primary cortical neurons (data not shown).




Figure 6
DHA and EPA increase the amounts of PrPC at the surface of ScGT1 cells. The amounts of PrPC (ng/ml) released from the surface of ScGT1 cells treated for 24 hours with different concentrations of DHA or EPA were plotted against the amounts of PrP^{Sc} (ng/ml) in ScGT1 cells treated for 7 days with the same concentrations of DHA (l) or EPA (m).

The amount of free cholesterol in cell membranes is partly determined by their fatty acid composition; the solubility of free cholesterol is dependent on the hydrophobic environment produced by the tight packing of saturated fatty acids [24]. The presence of double bonds in unsaturated fatty acids causes the acyl chain to be kinked; as a result, phospholipids containing PUFA cannot pack as tightly as phospholipids containing saturated fatty acids and do not sequester as much free cholesterol. Thus, the remodelling of membrane phospholipids to include increased amounts of DHA or EPA is expected to reduce the capacity of membranes to solubilise free cholesterol. The amounts of free cholesterol within cell membranes is tightly controlled [25,26] and excess free cholesterol trafficking into the endoplasmic reticulum (ER) is esterified by acyl-coenzyme A: cholesterol acyltransferase (ACAT) and stored in cytoplasmic droplets [27]. Our results are consistent with the hypothesis that treatment with DHA and EPA reduces the capacity of cell membranes to solubilise free cholesterol, resulting in increased cholesterol ester formation. This hypothesis also explains the observation that the addition of mevalonate did not reverse the effects of DHA and EPA. While mevalonate increased the amounts of free cholesterol in simvastatin-treated cells, in DHA or EPA-treated cells the newly synthesised cholesterol was not held in the membrane and was rapidly esterified. Simi-

Table 4: Treatment with DHA or EPA increases the amounts of PrPC at the cell surface

Treatment	Cell surface PrPC (ng/10 ⁶ cells)		
	Cortical Neurons	GTI cells	ScGTI cells
None	2.9 ± 0.4	1.8 ± 0.6	4.1 ± 0.8
1 μM AA	3.1 ± 0.4	2.1 ± 0.4	3.7 ± 1.1
1 μM DHA	4.8 ± 0.4 #	3.1 ± 0.6 #	8.6 ± 1.6 #
1 μM EPA	4.5 ± 0.5 #	2.8 ± 0.5 #	6.7 ± 1.2 #
1 μM LA	3.4 ± 0.6	2.5 ± 0.6	5 ± 0.7
1 μM LNA	3.2 ± 0.6	2.3 ± 0.5	5.8 ± 0.8 #
2 μM Simvastatin	0.6 ± 0.3 *	0.5 ± 0.2 *	0.7 ± 0.4 *

The amounts of PrPC at the surface of 10⁶ cells treated with 1 μM PUFA or 2 μM simvastatin for 24 hours were measured following digestion with PI-PLC (0.2 units/ml). Amounts of PrPC were measured by ELISA and are expressed as the mean average PrPC (ng/10⁶ cells) ± SD, n = 12. # = amounts of PrPC significantly higher than that of untreated cells (P < 0.01). * = amounts of PrPC significantly lower than that of untreated cells (P < 0.01).

larly, while the addition of mevalonate reversed the effects of simvastatin on PrP^{Sc} formation, it did not reverse the effects of DHA and EPA.

So how could changes in membrane composition affect PrP^{Sc} formation? The composition of cell membranes affects the aggregation of PrP^{Sc} and fibril formation [28]. Therefore, changes in cell membranes induced by DHA

and EPA may enhance the conversion of small PrP^{Sc} oligomers, that are thought to be sensitive to protease digestion (PrP^{Sc}-sen) [29], into the larger fibrillar, protease-resistant deposits of PrP^{Sc}. The amount of free cholesterol in cell membranes is also instrumental in the formation of lipid rafts [7]. These contain many signalling molecules, and an emerging paradigm is that of cell activation occurring as a consequence of individual rafts coalescing to form a platform capable of sustained cell activation. Therefore, changes in membrane free cholesterol caused by the incorporation of DHA or EPA into membrane phospholipids may affect lipid-raft formation and associated cellular functions [30,31]. In this study we examined the effects of PUFA treatment on PLA₂ activity, as PLA₂ has a critical role in PrP^{Sc} formation [14]. As activation of PLA₂ in ScGT1 cells is cholesterol-sensitive [5], treatment with DHA or EPA was expected to reduce PLA₂ activity. However, they significantly increased PLA₂ activity and PGE₂ production in ScGT1, ScN2a and SMB cells. The mechanisms by which DHA or EPA increased activation of PLA₂ are unclear. Since DHA triggers the formation of lipid rafts [32] it is possible that treatment with DHA or EPA strengthens the association between PLA₂ and PrP^{Sc} within a lipid raft. However, it should be noted that DHA may have other physical effects on membrane properties that are independent of cholesterol reduction [33]. For example, in some cells DHA released from membrane phospholipids by PLA₂ is metabolised into docosanoids [34]. The effects of such DHA metabolites are only just being elucidated and the possibility that specific docosanoids affect PrP^{Sc} formation cannot be discounted. Similarly, PUFA have been reported to affect gene regulation [35] and we do not exclude the possibility that the effects of DHA or EPA on PrP^{Sc} formation result from gene activation.

We examined the possibility that the increased PrP^{Sc} production in DHA or EPA-treated cells might be a consequence of their effects on the expression of PrP^C.




Figure 7
DHA and EPA increase the half-life of surface PrPC in neurons. The amounts of biotinylated-PrPC in untreated neurons (I), neurons treated with 1 μM DHA (s) or neurons treated with 1 μM EPA (m) measured in cell extracts taken at different time points after biotinylation. Values shown are the mean average amounts of biotinylated-PrPC (Units) ± SD, n = 9.

Treatment of neurons with DHA or EPA did not affect the total amounts of PrP^C in cell extracts, or the distribution of PrP^C between lipid rafts and the bulk membrane. However, it significantly increased the amounts of PrP^C expressed at the cell surface. This effect of DHA and EPA contrasted with that of the cholesterol synthesis inhibitors simvastatin or lovastatin, which reduced surface PrP^C expression [21]. Prior studies indicated that PrP^C, but not PrP^{Sc}, is released from cell membranes following PI-PLC digestion [20], and in the present studies, the PrP released from ScGT1 cells was protease-sensitive, indicating that the PrP released was indeed PrP^C. These assays were also performed on non-infected GT1 cells and cortical neurons with similar results; treatment with either DHA or EPA significantly increased the amounts of PrP^C at the cell surface, showing that the effects of DHA or EPA on PrP^C expression were not secondary to their effects on PrP^{Sc} formation.

These observations are relevant as antibody studies suggest that the conversion of PrP^C to PrP^{Sc} occurs at the cell surface or after internalisation from the cell surface [36]. Our hypothesis, that treatment with DHA or EPA increases the amount of PrP^C at the cell surface, a site where it could be readily converted to PrP^{Sc}, is supported by the positive correlation obtained between the amounts of PrP^C at the cell surface and PrP^{Sc} in ScGT1 cells. In addition, the half-life of surface PrP^C was greatly increased in DHA or EPA-treated cells. Taken together these results suggest that treatment with DHA or EPA alters endocytosis and intracellular trafficking of PrP^C, consistent with reports that the intracellular trafficking of PrP^C is critical for PrP^{Sc} formation [37,38]. The effect of DHA or EPA on PrP^C is relevant not only for prion diseases but may also have implications for Alzheimer's disease. The cellular PrP^C present in lipid rafts inhibits beta-secretase activity, reducing the cleavage of amyloid precursor protein and amyloid β formation [39]. Thus the regulation of PrP^C levels may represent an innovative approach for the modulation of amyloid deposition in the brain of individuals affected by Alzheimer's disease.

Conclusion

We have shown that treatment of prion-infected cells with DHA or EPA alters the composition of cell membranes; it decreased amounts of free cholesterol and increased cholesterol esters. In contrast to the effects of cholesterol synthesis inhibitors, treatment with DHA or EPA increased PrP^{Sc} formation. Treatment with DHA or EPA greatly increased the expression of PrP^C at the cell surface, a putative site for PrP^{Sc} formation, and altered cell signalling activity within prion-infected cells, increasing the activation of PLA₂ that is required for PrP^{Sc} formation [14]. Cholesterol depletion has been proposed as a therapeutic strategy for prion diseases, based on reports that chole-

sterol synthesis inhibitors reduced PrP^{Sc} formation. The studies reported here demonstrate that cholesterol depletion *per se* does not reduce PrP^{Sc} formation and cautions against such an approach. While these observations provide some insight into the composition of lipid rafts and the activation of signalling pathways that initiate the formation of PrP^{Sc}, future studies are needed to examine the precise relationship between free cholesterol, PrP^C expression and PrP^{Sc} formation.

Methods

Cell lines

Prion-infected ScGT1, ScN2a or SMB neuronal cell lines were grown in Ham's F12 medium supplemented with 2 mM glutamine, 2% foetal calf serum (FCS) and standard antibiotics (100 U/ml penicillin and 100 μ g/ml streptomycin). To measure the effect of PUFA on PrP^{Sc} formation, ScGT1, ScN2a or SMB cells were plated in 6-well plates (10⁵ cells/well) and cultured in the presence of PUFA, mevalonate or simvastatin. Cells were grown with daily changes of media and the amounts of cell-associated PrP^{Sc} were evaluated after 7 days. Cells were washed twice in phosphate-buffered saline (PBS) before cell extracts were obtained. Spent medium was collected daily to see if PrP^{Sc} was released into the supernatant. Spent media was digested with proteinase K (1 μ g/ml for 1 hour at 37°C); digestion was stopped with mixed protease inhibitors. The digested supernatant was concentrated by centrifugation with a 30 kDa filter and diluted to an equivalent of 10⁶ cells/ml.

Primary neuronal cultures

Primary cortical neurons were prepared from the brains of mouse embryos (day 15.5) after mechanical dissociation, cell sieving and isolation on histopaque (Sigma, Poole, UK). Neuronal precursors were plated (10⁶ cells/well) in 24-well plates coated with 5 μ g/ml poly-L-lysine in Ham's F12 containing 5% FCS for 2 hours. Cultures were shaken (600 rpm for 5 minutes) and non-adherent cells removed by two washes in PBS. Neurons were grown in neurobasal medium (NBM) containing B27 components (Invitrogen, Paisley, UK) for 7 days before they were incubated with test compounds. Immunohistochemistry showed that less than 3% of cells stained for GFAP (astrocytes) or for F4/80 (microglial cells).

Membrane extracts

Cells were homogenised in a buffer containing 10 mM Tris-HCl, 150 mM NaCl, 10 mM EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, 0.2% sodium dodecyl sulphate (SDS) at 10⁶ cells/ml. Mixed protease inhibitors (AEBSF, Aprotinin, Leupeptin, Bestain, Pepstatin A and E-46 (Sigma)) were added to some cell extracts. Membranes were prepared by repeated passage with a Wheaton homogeniser; nuclei and large fragments were removed

by centrifugation ($300 \times g$ for 5 minutes). To determine the amount of PrP^{Sc}, whole cell extract was digested with 1 $\mu\text{g/ml}$ proteinase K for 1 hour at 37°C, and digestion was stopped with mixed protease inhibitors. Digestion of GT1 cell extracts with 1 $\mu\text{g/ml}$ proteinase K for 1 hour at 37°C completely reduced the PrP signal; that is, complete digestion of PrP^C was achieved. The soluble material was split into two samples, one of which was heated to 95°C for 5 minutes and tested in a PrP-specific ELISA (see below). The other sample was mixed 1:1 with Laemmli buffer (Bio-Rad) containing β -mercaptoethanol and boiled for 5 minutes. This fraction was run on a 12% polyacrylamide gel (Invitrogen, Paisley, UK). Proteins were transferred onto a Hybond-ECL nitrocellulose membrane (Amersham Biosciences, UK) by semi-dry blotting. Membranes were blocked using 10% milk powder, and PrP was detected by incubation with a mouse monoclonal antibody (mAb) ICSM18 (D-Gen, <http://www.d-gen.co.uk>), followed by biotinylated rabbit anti-mouse IgG (Dako, Ely, UK) and ExtrAvidin-peroxidase (Sigma). Detection of bound antibody was by the enhanced chemiluminescence kit (Amersham Biosciences). Non-digested samples were boiled in Laemmli buffer containing β -mercaptoethanol for 5 minutes and run on a 15% polyacrylamide gel. Proteins were transferred onto a Hybond-P PVDF membrane (Amersham Biotech, UK) by semi-dry blotting. Membranes were blocked using 10% milk powder and β -actin was detected by incubation with a mouse mAb (clone AC-74, Sigma). Detection of bound antibody was by the enhanced chemiluminescence kit.

Isolation of detergent-resistant membranes (lipid rafts)

To differentiate between the normal bulk membrane and the lipid raft micro-domains, cells were homogenised in an ice-cold buffer containing 1% Triton \times 100, 10 mM Tris-HCl, 150 mM NaCl, 10 mM EDTA and mixed protease inhibitors at 10^6 cells/ml (as above). Membranes were prepared by repeated passage with a Wheaton homogeniser and nuclei and large fragments were removed by centrifugation ($300 \times g$ for 5 minutes at 4°C). The subsequent post-nuclear supernatant was incubated on ice (4°C) for 1 hour and centrifuged ($16,000 \times g$ for 30 minutes at 4°C). The supernatant was reserved as the normal bulk membrane while the insoluble pellet was homogenised in warm extraction buffer containing 10 mM Tris-HCl, 150 mM NaCl, 10 mM EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, 0.2% SDS and mixed protease inhibitors at an equivalent of 10^6 cells/ml, and centrifuged (10 minutes at $16,000 \times g$); the soluble material was reserved as the lipid raft fraction.

PrP ELISA

The amount of PrP present in cell extracts was determined in a sandwich ELISA using commercially available, defined mAbs as previously described [19]. Briefly, Nunc

Maxisorb immunoplates were coated with 0.5 $\mu\text{g/ml}$ mAb ICSM18 (D-Gen) which recognises amino acids 146 to 159 of murine PrP [40]. Samples were applied and detected with biotinylated mAb ICSM35 (D-Gen) (which recognises an epitope between amino acids 91 and 110) [41]. Biotinylated mAb was detected using extravidin-alkaline phosphatase and 1 mg/ml 4-nitrophenyl phosphate in a diethanolamine buffer (Sigma). Absorbance was measured on a microplate reader at 450 nm and the amount of PrP in cell extracts was calculated by reference to a standard curve of recombinant murine PrP (Prionics, Zurich, Switzerland); its limit of detection was 50 pg/ml.

Activated cPLA₂ ELISA

The activation of cPLA₂ is accompanied by phosphorylation of the 505 serine residue which can be measured by phospho-specific antibodies. The amounts of activated cPLA₂ in cells were measured by a sandwich ELISA using a capture antibody (mouse mAb anti-cPLA₂, clone CH-7, Upstate, Milton Keynes, UK) and a rabbit polyclonal anti-phospho-cPLA₂ (Cell Signalling Technology). Bound antibodies were detected with biotinylated anti-rabbit IgG (Dako), extravidin-alkaline phosphatase and 1 mg/ml 4-nitrophenyl phosphate in a diethanolamine buffer (Sigma). Absorbance was measured at 450 nm and the amounts of activated cPLA₂ were calculated from a standard curve using nonlinear regression. Samples were expressed as 'units cPLA₂' where 100 units was defined as the amount of activated cPLA₂ in 10^6 untreated cells. A standard curve was generated from this sample using sequential log 2 dilutions (range 100 to 1.56 units/well).

PGE₂ assay

The amounts of PGE₂ produced by cells were determined by using an enzyme-immunoassay kit (Amersham Biotech, Amersham, UK) according to the manufacturer's instructions. This assay is based on competition between unlabelled PGE₂ in the sample and a fixed amount of labelled PGE₂ for a PGE₂-specific antibody. The detection limit of this assay is 20 pg/ml.

Quantification of cell surface PrP^C

The amounts of PrP^C expressed at the cell surface were determined by treating cells with 0.2 units of PI-PLC for 1 hour at 37°C (10^6 cells/ml). PI-PLC is cell-impermeable and acts on the GPI anchors that tether some proteins, including PrP^C, to the cell surface. The amounts of PrP^C released into the culture supernatant following PI-PLC digestion were measured by PrP ELISA (as above).

Half-life of PrP^C

The half-life of surface PrP^C in neurons was determined by incubating 10^6 cells with PBS containing 10 $\mu\text{g/ml}$ membrane-impermeable sulfo-biotin-X-NHS (Pierce, Cramlington, UK) for 10 minutes. Cells were washed four times

with ice-cold PBS containing 10% FCS to remove unbound biotin and incubated in fresh NBM. Cell extracts were collected 1, 3, 6, 12, 24 and 48 hours later. The amounts of biotinylated PrP^C in cell extracts were measured in a modified ELISA. Maxisorb Immunoplates (Nunc, Roskilde, Denmark) were pre-coated with 10 µg/ml streptavidin (Sigma) and blocked with 10% milk powder. Samples were added for 1 hour and the amounts of bound biotinylated PrP^C were determined by incubation with the PrP-specific mouse mAb 4F2, anti-mouse IgG-alkaline phosphate and 1 mg/ml 4-nitrophenyl phosphate in a diethanolamine buffer. Absorbance was measured at 450 nm. The amounts of biotinylated PrP^C were expressed as units, where 100 units equalled the amount of biotinylated-PrP^C in 10⁶ untreated neurons 1 hour after biotinylation.

Cholesterol and protein content

Cellular cholesterol and protein content were determined in cell extracts. Protein concentrations were measured using a micro-BCA protein assay kit (Pierce, Cramlington, UK). The amounts of cholesterol were measured using the fluorometric Amplex Red cholesterol assay kit (Invitrogen), according to the manufacturer's instructions. Briefly, cholesterol is oxidised by cholesterol oxidase to yield hydrogen peroxide and ketones. The hydrogen peroxide reacts with 10-acetyl-3, 7-dihydroxyphenoxazine (Amplex Red reagent) to produce highly fluorescent resorufin, which is measured by excitation at 550 nm and emission detection at 590 nm. By performing the assay in the presence or absence of 50 units/ml cholesterol esterase and 20 µM TMP-15, which inhibits the esterification of free cholesterol, the assay can also determine the amounts of esterified cholesterol within samples.

Reagents

AA, DHA, DPA, DTA, EPA, ETA, LA, LNA, cholesterol myristate and cholesterol arachidonate were supplied by Sigma. Stock solutions were made in chloroform/methanol mixtures and frozen at 10 mM; they were thawed and diluted on the day of use. Mevalonate and simvastatin were from Calbiochem, Nottingham, UK.

Statistical analysis

Comparison of treatment effects was carried out using one and two-way analysis of variance techniques as appropriate. *Post hoc* comparisons of means were performed as necessary. For all statistical tests significance was set at the 1% level.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

CB, MT and LD were responsible for the conception, planning and performance of experiments and for writing the manuscript. MT, AW and MS contributed to the planning of experiments, interpretation of results and the writing of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This research was supported by the European Commission Framework Package 6 Network of Excellence 'NeuroPrion'.

References

1. Prusiner SB: **Prions**. *Proc Natl Acad Sci USA* 1998, **95**:13363-13383.
2. Jeffrey M, Goodsir CM, Bruce ME, McBride PA, Fraser JR: **In vivo toxicity of prion protein in murine scrapie: ultrastructural and immunogold studies**. *Neuropathol Appl Neurobiol* 1997, **23**:93-101.
3. Prusiner SB: **Novel proteinaceous infectious particles cause scrapie**. *Science* 1982, **216**:136-144.
4. Taraboulos A, Scott M, Semenov A, Avrahami D, Laszlo L, Prusiner SB, Avraham D: **Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform**. *J Cell Biol* 1995, **129**:121-132.
5. Bate C, Salmons M, Diomedea L, Williams A: **Squalenstatin cures prion-infected neurones and protects against prion neurotoxicity**. *J Biol Chem* 2004, **279**:14983-14990.
6. Hagiwara K, Nakamura Y, Nishijima M, Yamakawa Y: **Prevention of prion propagation by dehydrocholesterol reductase inhibitors in cultured cells and a therapeutic trial in mice**. *Biol Pharm Bull* 2007, **30**:835-838.
7. Pike LJ: **Lipid rafts: heterogeneity on the high seas**. *Biochem J* 2004, **378**:281-292.
8. Lucero HA, Robbins PW: **Lipid rafts-protein association and the regulation of protein activity**. *Arch Biochem Biophys* 2004, **426**:208-224.
9. Vey M, Pilkuhn S, Wille H, Nixon R, DeArmond SJ, Smart EJ, Anderson RG, Taraboulos A, Prusiner SB: **Subcellular colocalization of the cellular and scrapie prion proteins in caveolae-like membranous domains**. *Proc Natl Acad Sci USA* 1996, **93**:14945-14949.
10. Siddiqui RA, Shaikh SR, Sech LA, Yount HR, Stillwell W, Zaloga GP: **Omega 3-fatty acids: health benefits and cellular mechanisms of action**. *Mini Rev Med Chem* 2004, **4**:859-871.
11. Farooqui AA, Horrocks LA, Farooqui T: **Deacylation and reacylation of neural membrane glycerophospholipids**. *J Mol Neurosci* 2000, **14**:123-135.
12. Stulnig TM, Huber J, Leitinger N, Imre EM, Angelisova P, Nowotny P, Waldhausl W: **Polyunsaturated eicosapentaenoic acid displaces proteins from membrane rafts by altering raft lipid composition**. *J Biol Chem* 2001, **276**:37335-37340.
13. Ma DWL, Seo J, Davidson LA, Callaway ES, Fan YY, Lupton JR, Chapkin RS: **n-3 PUFA alter caveolae lipid composition and resident protein localization in mouse colon**. *FASEB J* 2004, **18**:1040-1020.
14. Bate C, Reid S, Williams A: **Phospholipase A₂ inhibitors or platelet activating factor antagonists prevent prion replication**. *J Biol Chem* 2004, **279**:36405-36411.
15. Brandner S, Isenmann S, Raeber A, Fischer M, Sailer A, Kobayashi Y, Marino S, Weissmann C, Aguzzi A: **Normal host prion protein necessary for scrapie-induced neurotoxicity**. *Nature* 1996, **379**:339-343.
16. Mallucci G, Dickinson A, Linehan J, Klöhn PC, Brandner S, Collinge J: **Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis**. *Science* 2003, **302**:871-874.
17. Fevrier B, Vilette D, Archer F, Loew D, Faigle W, Vidal M, Laude H, Raposo G: **Cells release prions in association with exosomes**. *Proc Natl Acad Sci USA* 2004, **101**:9683-9688.
18. Istvan ES, Deisenhofer J: **Structural mechanism for statin inhibition of HMG-CoA reductase**. *Science* 2001, **292**:1160-1164.

19. Bate C, Tayebi M, Williams A: **Sequestration of free cholesterol in cell membranes by prions correlates with cytoplasmic phospholipase A₂ activation.** *BMC Biol* 2008, **6**:8.
20. Caughey B, Neary K, Buller R, Ernst D, Perry LL, Chesebro B, Race RE: **Normal and scrapie-associated forms of prion protein differ in their sensitivities to phospholipase and proteases in intact neuroblastoma cells.** 1990, **64**:1093-1101.
21. Gilch S, Kehler C, Schatzl HM: **The prion protein requires cholesterol for cell surface localization.** *Mol Cell Neurosci* 2006, **31**:346-353.
22. Fai Mok SW, Thelen KM, Riemer C, Bamme T, Gultner S, Lutjohann D, Baier M: **Simvastatin prolongs survival times in prion infections of the central nervous system.** *Biochem Biophys Res Comm* 2006, **348**:697-702.
23. Kempster S, Bate C, Williams A: **Simvastatin treatment prolongs the survival of scrapie-infected mice.** *Neuroreport* 2007, **18**:479-482.
24. Schroeder F, Gallegos AM, Atshaves BP, Storey SM, McIntosh AL, Petrescu AD, Huang H, Starodub O, Chao H, Yang H, Frolov A, Kier AB: **Recent advances in membrane microdomains: rafts, caveolae, and intracellular cholesterol trafficking.** *Exp Biol Med* 2001, **226**:873-890.
25. Maxfield FR, Wustner D: **Intracellular cholesterol transport.** *J Clin Invest* 2002, **110**:891-898.
26. Simons K, Ilkonen E: **How cells handle cholesterol.** *Science* 2000, **290**:1721-1726.
27. Chang TY, Chang CCY, Cheng D: **Acyl-coenzyme A:cholesterol acyltransferase.** *Ann Rev Biochem* 1997, **66**:613-638.
28. Pinheiro TJ: **The role of rafts in the fibrillization and aggregation of prions.** *Chem Phys Lipids* 2006, **141**:66-71.
29. Tzaban S, Friedlander G, Schonberger O, Horonchik L, Yedidia Y, Shaked G, Gabizon R, Taraboulos A: **Protease-sensitive scrapie prion protein in aggregates of heterogeneous sizes.** *Biochemistry* 2002, **41**:12868-12875.
30. Shaikh SR, Edidin M: **Polyunsaturated fatty acids, membrane organization, T cells, and antigen presentation.** *Am J Clin Nutr* 2006, **84**:1277-1289.
31. Ma DWL, Seo J, Switzer KC, Fan YY, McMurray DN, Lupton JR, Chapkin RS: **n-3 PUFA and membrane microdomains: a new frontier in bioactive lipid research.** *J Nutr Biochem* 2004, **15**:700-706.
32. Shaikh SR, Cherezov V, Caffrey M, Stillwell W, Wassall SR: **Interaction of cholesterol with a docosahexaenoic acid-containing phosphatidylethanolamine: trigger for microdomain/raft formation?** *Biochemistry* 2003, **42**:12028-12037.
33. Wassall SR, Stillwell W: **Docosahexaenoic acid domains: the ultimate non-raft membrane domain.** *Chem Phys Lipids* 2008, **153**:57-63.
34. Serhan N: **Novel [omega] - 3-derived local mediators in anti-inflammation and resolution.** *Pharmacol Ther* 2005, **105**:7-21.
35. Jump DB: **Dietary polyunsaturated fatty acids and regulation of gene transcription.** *Curr Opin Lipidol* 2002, **13**:155-164.
36. Enari M, Flechsig E, Weissmann C: **Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody.** *Proc Natl Acad Sci USA* 2001, **98**:9295-9299.
37. Beranger F, Mange A, Goud B, Lehmann S: **Stimulation of PrP(C) retrograde transport toward the endoplasmic reticulum increases accumulation of PrP(Sc) in prion-infected cells.** *J Biol Chem* 2002, **277**:38972-38977.
38. Gilch S, Winklhofer KF, Groschup MH, Nunziante M, Lucassen R, Spielhauer C, Muranyi W, Riesner D, Tatzelt J, Schatzl HM: **Intracellular re-routing of prion protein prevents propagation of PrP(Sc) and delays onset of prion disease.** *EMBO J* 2001, **20**:3957-3966.
39. Parkin ET, Watt NT, Hussain I, Eckman EA, Eckman CB, Manson JC, Baybutt HN, Turner AJ, Hooper NM: **Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein.** *Proc Natl Acad Sci USA* 2007, **104**:11062-11067.
40. White AR, Enever P, Tayebi M, Mushens R, Linehan J, Brandner S, Anstee D, Collinge J, Hawke S: **Monoclonal antibodies inhibit prion replication and delay the development of prion disease.** *Nature* 2003, **422**:80-83.
41. Beringue V, Mallinson G, Kaisar M, Tayebi M, Sattar Z, Jackson G, Anstee D, Collinge J, Hawke S: **Regional heterogeneity of cellular prion protein isoforms in the mouse brain.** *Brain* 2003, **126**:2065-2073.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

